Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his own motivations for working in the industry.
Mr. Weppner, you were appointed General Manager of AbbVie Switzerland less than a year ago. What is your mandate for the Swiss affiliate?
We want to be a meaningful player and transforming our organization is one of our key objectives. That means we have to constantly open our minds to change.
